Lakefront Biotherapeutics (LKFT) Free Cash Flow (2014 - 2026)
Lakefront Biotherapeutics (LKFT) reported Free Cash Flow of -$110.6 million for Q1 2026, down 177.53% year-over-year from $142.7 million in Q1 2025, and down 84.22% quarter-over-quarter from -$60.0 million in Q4 2025.
Lakefront Biotherapeutics (LKFT) Free Cash Flow (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has 13 years of Free Cash Flow data on file, last reported at -$110.6 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$110.6 million, down 177.53% year-over-year; the trailing twelve-month figure through Mar 2026 was -$162.6 million (down 164.0% YoY), and the FY2025 annual result was -$315.6 million, up 12.28% from the prior year.
- Free Cash Flow retreated to -$110.6 million in Q1 2026 per LKFT's latest filing, from -$60.0 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $4.7 million in Q2 2025 and troughed at -$231.7 million in Q4 2022.
- A 5-year average of -$64.3 million and a median of -$59.2 million in 2022 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2025 and 2026: Free Cash Flow soared 71.99% in 2025, then slumped 177.53% in 2026.
- A 5-year view of Free Cash Flow shows it stood at -$231.7 million in 2022, then jumped by 66.25% to -$78.2 million in 2023, then surged by 61.66% to -$30.0 million in 2024, then sank by 100.32% to -$60.0 million in 2025, then plunged by 84.22% to -$110.6 million in 2026.
- Business Quant data shows LKFT's Free Cash Flow at -$110.6 million in Q1 2026, -$60.0 million in Q4 2025, and $3.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 63,220.27 |
| 10 | Lakefront Biotherapeutics | 9.64 Bn | 9.64 Bn | 1.97 Mn | -110.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -110.62 Mn |
| Mar 31, 2026 | -110.62 Mn |
| Dec 31, 2025 | -60.05 Mn |
| Dec 31, 2025 | -60.05 Mn |
| Sep 30, 2025 | 3.33 Mn |
| Sep 30, 2025 | 3.33 Mn |
| Jun 30, 2025 | 4.70 Mn |
| Jun 30, 2025 | 4.70 Mn |
| Mar 31, 2025 | -39.86 Mn |
| Mar 31, 2025 | -39.86 Mn |
| Dec 31, 2024 | -29.98 Mn |
| Dec 31, 2024 | -29.98 Mn |
| Sep 30, 2024 | 4.65 Mn |
| Sep 30, 2024 | 4.65 Mn |
| Jun 30, 2024 | 3.58 Mn |
| Jun 30, 2024 | 3.58 Mn |
| Mar 31, 2024 | -142.28 Mn |
| Mar 31, 2024 | -142.28 Mn |
| Dec 31, 2023 | -78.19 Mn |
| Dec 31, 2023 | -78.19 Mn |